Acetohydroxyacid synthase (AHAS) is the first enzyme in the branched-chain amino acid biosynthesis pathway in bacteria. Bioinformatics analysis revealed that the Mycobacterium tuberculosis genome contains four genes (ilvB1, ilvB2, ilvG and ilvX) coding for the large catalytic subunit of AHAS, whereas only one gene (ilvN or ilvH) coding for the smaller regulatory subunit of this enzyme was found. In order to understand the physiological role of AHAS in survival of the organism in vitro and in vivo, we inactivated the ilvB1 gene of M. tuberculosis. The mutant strain was found to be auxotrophic for all of the three branched-chain amino acids (isoleucine, leucine and valine), when grown with either C6 or C2 carbon sources, suggesting that the ilvB1 gene product is the major AHAS in M. tuberculosis. Depletion of these branched chain amino acids in the medium led to loss of viability of the ΔilvB1 strain in vitro, resulting in a 4-log reduction in colony-forming units after 10 days. Survival kinetics of the mutant strain cultured in macrophages maintained with sub-optimal concentrations of the branched-chain amino acids did not show any loss of viability, indicating either that the intracellular environment was rich in these amino acids or that the other AHAS catalytic subunits were functional under these conditions. Furthermore, the growth kinetics of the ΔilvB1 strain in mice indicated that although this mutant strain showed defective growth in vivo, it could persist in the infected mice for a long time, and therefore could be a potential vaccine candidate.
AlexanderJ. E.,
AndrewP. W.,
JonesD.,
RobertsI. S.1993; Characterization of an aromatic amino acid-dependent Listeria monocytogenes mutant: attenuation, persistence, and ability to produce protective immunity in mice. Infect Immun 61:2245–2248
AtkinsT.,
PriorR. G.,
MackK.,
RussellP.,
NelsonM.,
OystonP. C.,
DouganG.,
TitballR. W.2002; A mutant of Burkholderia pseudomallei, auxotrophic in the branched chain amino acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis. Infect Immun 70:5290–5294
BarakZ.,
ChipmanD. M.,
GollopN.1987; Physiological implications of the specificity of acetohydroxy acid synthase isozymes of enteric bacteria. J Bacteriol 169:3750–3756
BoigegrainR. A.,
LiautardJ. P.,
KöhlerS.2005; Targeting of the virulence factor acetohydroxyacid synthase by sulfonylureas results in inhibition of intramacrophagic multiplication of Brucella suis
. Antimicrob Agents Chemother 49:3922–3925
ChoiK. J.,
YuY. G.,
HahnH. G.,
ChoiJ. D.,
YoonM. Y.2005; Characterization of acetohydroxyacid synthase from Mycobacterium tuberculosis and the identification of its new inhibitor from the screening of a chemical library. FEBS Lett 579:4903–4910
ColeS. T.,
EiglmeierK.,
ParkhillJ.,
JamesK. D.,
ThomsonN. R.,
WheelerP. R.,
HonoréN.,
GarnierT.,
ChurcherC.other authors2001; Massive gene decay in the leprosy bacillus. Nature 409:1007–1011
DaileyF. E.,
CronanJ. E.Jr,
MaloyS. R.1987; Acetohydroxy acid synthase I is required for isoleucine and valine biosynthesis by Salmonella typhimurium LT2 during growth on acetate or long-chain fatty acids. J Bacteriol 169:917–919
EwannF.,
JacksonM.,
PetheK.,
CooperA.,
MielcarekN.,
EnsergueixD.,
GicquelB.,
LochtC.,
SupplyP.2002; Transient requirement of the PrrA-PrrB two-component system for early intracellular multiplication of Mycobacterium tuberculosis
. Infect Immun 70:2256–2263
FilhoJ. C.,
BergströmJ.,
StehleP.,
FürstP.1997; Simultaneous measurements of free amino acid patterns of plasma, muscle and erythrocytes in healthy human subjects. Clin Nutr 16:299–305
HondalusM. K.,
BardarovS.,
RussellR.,
ChanJ.,
JacobsW. R.,
BloomB. R.2000; Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis
. Infect Immun 68:2888–2898
LaRossaR. A.,
SchlossJ. V.1984; The sulfonylurea herbicide sulfometuron methyl is an extremely potent and selective inhibitor of acetolactate synthase in Salmonella typhimurium
. J Biol Chem 259:8753–8757
Muñoz-ElíasE. J.,
McKinneyJ. D.2005; Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med 11:638–644
ParishT.,
StokerN. G.2000; Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosistlyAplcABC mutant by gene replacement. Microbiology 146:1969–1975
PascopellaL.,
CollinsF. M.,
MartinJ. M.,
LeeM. H.,
HatfullG. F.,
StoverC. K.,
BloomB. R.,
JacobsW. R.Jr1994; Use of in vivo complementation in Mycobacterium tuberculosis to identify a genomic fragment associated with virulence. Infect Immun 62:1313–1319
PoratI.,
VinogradovM.,
VyazmenskyM.,
LuC. D.,
ChipmanD. M.,
AbdelalA. T.,
BarakZ.2004; Cloning and characterization of acetohydroxyacid synthase from Bacillus stearothermophilus
. J Bacteriol 186:570–574
SambandamurthyV. K.,
JacobsW. R.Jr2005; Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect 7:955–961
SmithD. A.,
ParishT.,
StokerN. G.,
BancroftG. J.2001; Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 69:1142–1150
SohnH.,
LeeK. S.,
KoY. K.,
RyuJ. W.,
WooJ. C.,
KooD. W.,
ShinS. J.,
AhnS. J.,
ShinA. R.other authors2008; In vitro and ex vivo activity of new derivatives of acetohydroxyacid synthase inhibitors against Mycobacterium tuberculosis and non-tuberculous mycobacteria. Int J Antimicrob Agents 31:567–571
StoverC. K.,
de la CruzV. F.,
FuerstT. R.,
BurleinJ. E.,
BensonL. A.,
BennettL. T.,
BansalG. P.,
YoungJ. F.,
LeeM. H.other authors1991; New use of BCG for recombinant vaccines. Nature 351:456–460
SunR.,
ConverseP. J.,
KoC.,
TyagiS.,
MorrisonN. E.,
BishaiW. R.2004; Mycobacterium tuberculosis ECF sigma factor sigC is required for lethality in mice and for the conditional expression of a defined gene set. Mol Microbiol 52:25–38
ZoharY.,
EinavM.,
ChipmanD. M.,
BarakZ.2003; Acetohydroxyacid synthase from Mycobacterium avium and its inhibition by sulfonylureas and imidazolinones. Biochim Biophys Acta164997–105